Victory Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Victory Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.81M	Buy	83,544 +2,973	+4%	+$263K	0.01%	1120
2025 Q4	$7.04M	Sell	80,571 -4,923	-6%	-$403K	﹤0.01%	1174
2025 Q3	$5.68M	Sell	85,494 -5,438	-6%	-$309K	﹤0.01%	1302
2025 Q2	$5.03M	Sell	90,932 -11,479	-11%	-$551K	﹤0.01%	1322
2025 Q1	$4.95M	Sell	102,411 -138,406	-57%	-$5.8M	0.01%	1283
2024 Q4	$9.3M	Buy	240,817 +110,020	+84%	+$4.8M	0.01%	1108
2024 Q3	$5.89M	Buy	130,797 +123,647	+1,729%	+$5M	0.01%	1235
2024 Q2	$248K	Sell	7,150 -58	-0.8%	-$1.7K	﹤0.01%	2149
2024 Q1	$209K	Buy	+7,208	New	+$196K	﹤0.01%	2213
2022 Q1	–	Sell	-9,612	Closed	-$329K	–	2795
2021 Q4	$329K	Buy	+9,612	New	+$304K	﹤0.01%	2351
2021 Q3	–	Sell	-845,199	Closed	-$37.9M	–	2835
2021 Q2	$37.9M	Buy	+845,199	New	+$27.9M	0.04%	667
2020 Q2	–	Sell	-6,652	Closed	-$46K	–	3087
2020 Q1	$46K	Buy	+6,652	New	+$49.8K	﹤0.01%	2809
2019 Q4	–	Sell	-3,250	Closed	-$39K	–	3109
2019 Q3	$39K	Buy	+3,250	New	+$41K	﹤0.01%	2795

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Victory Capital Management's PTGX Position: Q1 2026 in Review

Victory Capital Management increased its Protagonist Therapeutics (PTGX) stake by 3.7% in Q1 2026, buying an estimated $263K and bringing the position to 83,544 shares worth $8.81M. The position accounts for 0.01% of the portfolio, ranked #1120.

Victory Capital Management first reported a position in PTGX in Q3 2019 and has held it in 13 quarters since. The position peaked at $37.9M in Q2 2021. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

Victory Capital Management held 83,544 shares of Protagonist Therapeutics worth $8.81M as of Q1 2026.
Victory Capital Management bought 2,973 Protagonist Therapeutics shares in Q1 2026, an estimated $263K.
Protagonist Therapeutics made up 0.01% of Victory Capital Management's portfolio in Q1 2026, its #1120 holding.
Victory Capital Management first reported a position in Protagonist Therapeutics in Q3 2019 and has held it in 13 quarters since.
Victory Capital Management's Protagonist Therapeutics position peaked at $37.9M in Q2 2021.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.